Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001628280-25-000673
Filing Date
2025-01-06
Accepted
2025-01-06 18:07:32
Documents
1
Period of Report
2025-01-02

Document Format Files

Seq Description Document Type Size
1 FORM 4 wk-form4_1736204845.html 4  
1 FORM 4 wk-form4_1736204845.xml 4 4286
  Complete submission text file 0001628280-25-000673.txt   6086
Mailing Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105
Business Address 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702
ARROWHEAD PHARMACEUTICALS, INC. (Issuer) CIK: 0000879407 (see all company filings)

EIN.: 460408024 | State of Incorp.: DE | Fiscal Year End: 0930
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address ARROWHEAD RESEARCH CORPORATION 201 SOUTH LAKE AVENUE, SUITE 703 PASADENA CA 91101
Business Address
Anzalone Christopher Richard (Reporting) CIK: 0001423029 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38042 | Film No.: 25512737